-Oral Presentation at ESGCT Highlights Potential of JCR’s Proprietary JUST-AAV Platform to Facilitate More Efficient Delivery While Reducing Liver Tropism- HYOGO, Japan–(BUSINESS WIRE)–JCR Pharmaceuticals Co., Ltd. (TSE 4552; “JCR”), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, today presented non-clinical data demonstrating the ability of its proprietary JUST-AAV capsid … [Read more…]

BOSTON–(BUSINESS WIRE)–#AASLD–nChroma Bio (“nChroma”), a genetic medicines company advancing in vivo delivery of innovative cargoes to overcome the limitations of existing therapies, today announced the acceptance of three abstracts, including a poster of distinction, at the upcoming AASLD Liver Meeting®, taking place November 7 to 11, 2025, in Washington, D.C. “At AASLD, we’re showcasing the … [Read more…]

First evaluation of benefit-to-burden for new screening options using methodologies adopted by the United States Preventive Services Task Force Noninvasive test performance is critical to support patient outcomes and reduce burden on limited colonoscopy capacity MADISON, Wis.–(BUSINESS WIRE)–Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests today announced the publication … [Read more…]

TOKYO–(BUSINESS WIRE)–RIBOMIC, Inc. (TOKYO:4591), a clinical-stage pharmaceutical company specializing in aptamer therapeutics, has conducted a Phase 2 clinical trial of umedaptanib pegol (anti-FGF2 aptamer) in pediatric patients (ages 5-14) with achondroplasia (ACH). The company announced today that the administration of the high-dose (0.6 mg/kg) subcutaneous injection (once biweekly) group (Cohort 2 Note 1) has completed … [Read more…]

U.S. News Honor Roll of Best Children’s Hospitals distinguishes CHLA with six specialties ranking in top 10 in the nation LOS ANGELES–(BUSINESS WIRE)–As a leader in pediatric academic medicine for nearly 125 years, Children’s Hospital Los Angeles (CHLA) continues to fulfill its mission by advancing care and making discoveries that enhance and save lives. Today, … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Stability Testing of Pharmaceuticals and Biopharmaceuticals Training Course (Nov 10th – Nov 11th, 2025)” training has been added to ResearchAndMarkets.com’s offering. By attending this intensive two-day seminar, delegates will learn how to: Carry out appropriate stability studies and manage stability samples and facilities Design stability studies that are suitable for global marketing Increase … [Read more…]

Findings from KONFIDENT and KONFIDENT-S show rapid, effective treatment of HAE attacks among European participants; patient survey highlights barriers linked to injectable therapies FRAMINGHAM, Mass. & SALISBURY, England–(BUSINESS WIRE)–KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced new data from its KONFIDENT and KONFIDENT-S studies of EKTERLY® (sebetralstat), the first and only oral on-demand treatment for hereditary … [Read more…]

Company highlights innovative biologic solutions and hosts Taste of Iceland event featuring a keynote on soft-tissue repair NEW ORLEANS–(BUSINESS WIRE)–#kerecis–Kerecis, the company pioneering the use of sustainably sourced fish skin in cellular therapy and tissue regeneration, will present its expanding portfolio of fish-skin grafts at Plastic Surgery The Meeting (“PSTM”) 2025, taking place October 9–12 … [Read more…]

The collaboration with Amgen reduces out-of-pocket costs for patients and expands access to an innovative cholesterol-lowering therapy SANTA MONICA, Calif.–(BUSINESS WIRE)–GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced the availability of Repatha® (evolocumab), a cholesterol-lowering therapy, at a significantly reduced cash price. Starting today, patients can use GoodRx to … [Read more…]

DENVER & MINNEAPOLIS–(BUSINESS WIRE)–OneMedNet Corporation (Nasdaq: ONMD) has selected Palantir Technologies (Nasdaq: PLTR) to transform the healthcare AI and Real-World Data (RWD) analytics marketplace. Palantir’s Artificial Intelligence Platform will provide the infrastructure for OneMedNet’s iRWD™ near real-time AI powered provider network (“network”) enabling OneMedNet to empower life sciences, medical device, and research organizations with anonymized, … [Read more…]